Behavioural Neurology / 2017 / Article / Tab 1

Research Article

Prevalence of Anxiety among Hungarian Subjects with Parkinson’s Disease

Table 1

Demographic and disease-specific data of the study population () participating in the validation phase.

Mean or countStandard deviation or percentage

Age (years)65.89.8
Education (years)12.53.2
Disease duration (years)7.26.4
Disease duration (years)7.26.4
Type of disease
 Tremor dominant6132.1%
 Akinetic rigid7941.6%
Hoehn and Yahr Stage
 Mild (1 & 2)10957.3%
 Moderate (3)4322.7%
 Severe (4 & 5)3820.0%
Levodopa dosage (in LED mg)472.8510.1
Dopamine agonist usage (in LED mg)165.8219.3
Antiparkinson medication (in LED mg)677.5600.6
MDS-UPDRS ME35.015.9
Nonmotor Symptoms Scale53.938.8
Montreal Cognitive Assessment22.74.4
Beck Depression Inventory11.78.8
Lille Apathy Rating Scale−22.59.5
Hamilton Anxiety Scale13.16.7
Parkinson Anxiety Scale (Part A)7.04.6
Parkinson Anxiety Scale (Part B)2.42.9
Parkinson Anxiety Scale (Part C)1.92.3
Parkinson Anxiety Scale (total score)11.38.4

LED = levodopa equivalent dosage; MDS-UPDRS = Movement Disorders Society-sponsored version of Unified Parkinson’s Disease Rating Scale; MDS-UPDRS M-EDL = motor experiences of daily living (Part II of MDS-UPDRS); MDS-UPDRS nM-EDL = nonmotor experiences of daily living (Part I of MDS-UPDRS); SD = standard deviation.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.